Executive Officers

 

Maurice Zauderer, Ph.D.

Maurice Zauderer, Ph.D. has served as our President and Chief Executive Officer and a member of our board of directors since our inception in April 2001. Prior to founding the company, Dr. Zauderer was an Associate Professor at the University of Rochester and has also held senior faculty positions at Columbia University. During his academic career, Dr. Zauderer held the position of visiting scientist at the Laboratory of Cell Biology, the Ontario Cancer Institute and the National Cancer Institute. Dr. Zauderer received a B.S. in Physics from Yeshiva University and a Ph.D. in Cell Biology from the Massachusetts Institute of Technology. We believe that Dr. Zauderer’s experience as an executive officer and his knowledge in biological sciences, immunology and oncology give him the qualifications and skills to serve on our board of directors.


Steven P. Cobourn, C.P.A.

Steven P. Cobourn has served as our Chief Financial Officer since May 2014. From December 2003 to April 2014, Mr. Cobourn was the Vice President of Finance and Treasurer of Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Maryland Medicinal Laboratories, Inc., each a subsidiary of Otsuka Holdings Co., Ltd., a Japanese publicly traded pharmaceutical company. Prior to this, Mr. Cobourn served in various roles at these Otsuka entities in finance and corporate planning. He was also a certified public accountant at accounting firm Hass & Company LLC. Mr. Cobourn received a B.S. in Business Administration from Drexel University.


Raymond E. Watkins

Raymond E. Watkins has served as our Senior Vice President and Chief Operating Officer since January 2008. Mr. Watkins previously served as our Vice President and Operations Officer from July 2001 to December 2008. Prior to joining us, Mr. Watkins served in various roles in operations and manufacturing at Life Technologies, Inc., a privately held life science company, which merged with Invitrogen Corporation in September 2000.


John E. Leonard, Ph.D.

John E. Leonard, Ph.D. has served as our Senior Vice President, Development since January 2009. Prior to joining us, Dr. Leonard served as a principal at John Leonard Consulting, LLC from September 2005 to January 2009. From February 2003 until September 2009, he was the Vice President, Program Executive of Biogen Idec, Inc., a publicly traded biotechnology company, and from August 1988 until January 2003 he served in various roles in product development, regulatory affairs and quality assurance at IDEC Pharmaceuticals Corporation, which merged with Biogen, Inc. to form Biogen Idec, Inc. Dr. Leonard received a B.S. in Chemistry and an M.S. in Chemistry and Biochemistry from California State University, Long Beach, and a Ph.D. in Biochemistry from the University of California, Riverside.


Ernest S. Smith, Ph.D.

Ernest S. Smith, Ph.D. has served as our Senior Vice President, Research and Chief Scientific Officer since December 2008. Dr. Smith previously served as our Vice President, Research and Chief Scientific Officer from April 2003 to December 2008 and our Research Director from June 2001 to April 2003. Prior to joining us, Dr. Smith was a research scientist at the University of Rochester. Dr. Smith received a B.A. in Biology from St. John Fisher College, and an M.S. and a Ph.D. in Immunology from the University of Rochester.

 

Directors

 

Albert D. Friedberg

Albert D. Friedberg has served as chairman of our board of directors since our inception in April 2001.  Mr. Friedberg has also served as the Chief Executive Officer and President and a director of Friedberg Mercantile Group Ltd., a Toronto-based commodities and investment management firm, since founding the company in 1971. Since 1978, he served as the President and Chief Investment Strategist for the Friedberg Group of Funds. Mr. Friedberg was appointed as a member of the Commodity Futures Advisory Board of Ontario in 1979, and served as chairman of the Toronto Futures Exchange from March 1985 to June 1988. Mr. Friedberg received a B.A. in Economics from Johns Hopkins University and an M.B.A. in International Banking from Columbia University. We believe that Mr. Friedberg’s experience in the financial and investment management industry, and his experience as the Chief Executive Officer and President and service as a director of Friedberg Mercantile Group give him the qualifications and skills to serve on our board of directors.


Alejandro M. Berlin, M.D. MSc

Alejandro M. Berlin, M.D. MSc has served as a member of our board of directors since February 2015. Since January 2007, Dr. Berlin has served as a radiation oncologist at Clinica Alemana Santiago, a Chile-basedhealth service provider, and at Tel Hashomer Hospital, a Israel-based health service provider. From January 2013 to December 2014, he was also a radiation oncology clinical research fellow at Princess Margaret Cancer Centre, a Toronto-based health service provider. Dr. Berlin is a member of the Canadian Prostate Cancer (CPC-Gene) project, which is part of the International Cancer Genome Consortium. Dr. Berlin received his medical degree from the Pontificia Universidad Cato´lica de Chile and a Master of Science from the Institute of Medical Sciences, University of Toronto. We believe that Dr. Berlin’s experience in the oncology field and in clinical research gives him the qualifications and skills to serve on our board of directors.


Alan L. Crane

Alan L. Crane has served as a member of our board of directors since March 2003. Since February 2002, Mr. Crane has served as a partner and entrepreneur at Polaris Partners, a technology- and healthcare-focused venture capital firm. Since May 2011, he has also served as the President and Chief Executive Officer of XTuit Pharmaceuticals, Inc., a privately held biotechnology company. From April 2013 to September 2014, Mr. Crane was the President of Arsia Therapeutics, Inc., a privately held biotechnology company. He also served from 2005 to 2009 as the Chief Executive Officer of Cerulean Pharma Inc., from 2002 to 2006 as the President and Chief Executive Officer of Momenta Pharmaceuticals, Inc., and prior to joining Polaris Partners as the Senior Vice President of Global Corporate Development at Millennium Pharmaceuticals, Inc. Mr. Crane serves on the boards of publicly traded life science companies Cerulean and T2 Biosystems, Inc., and serves on the board of privately held life science companies. Previously, he served on the boards of Momenta, Sirtris Pharmaceuticals, Inc. (acquired by GlaxoSmithKline), Adnexus Therapeutics, Inc. (acquired by Bristol Myers Squibb), Ocular Therapeutix, Inc. and Hydra Biosciences, Inc. Mr. Crane received a B.A., an M.A. and an M.B.A. from Harvard University. We believe that Mr. Crane’s experience in the venture capital industry, his experience as an executive at other successful life science companies, and his service as a director and chief executive officer of other publicly traded and privately held life science companies give him the qualifications and skills to serve on our board of directors.


Jacob B. Frieberg

Jacob B. Frieberg has served as a member of our board of directors since February 2015. Mr. Frieberg has also served as a principal at The WTF Group, a Toronto-based property management company, since founding the company in 1984. Prior to that time, he was the Vice President at Rockford Developments, a Calgary-based multi-family building company. Mr. Frieberg received a B.A. in Economics from the University of Western Ontario. We believe that Mr. Frieberg’s experience in business, including his management responsibility, gives him the qualifications, skills and financial expertise to serve on our board of directors.


J. Jeffrey Goater

J. Jeffrey Goater has served as a member of our board of directors since May 2013. Since April 2015, Mr. Goater has served as the Senior Vice President, Finance and Business Development at Voyager Therapeutics, Inc., a privately held gene therapy company. Prior to that time, he was the Vice President of Business Development at Voyager since September 2013. From April 2013 to July 2013, Mr. Goater was the Vice President, Head of Business Development at Synageva BioPharma Corp., a publicly traded biopharmaceutical company. From April 2008 to April 2013, he worked for Evercore Partners Inc., a publicly traded investment banking advisory firm, serving first as Vice President, Healthcare Strategic Advisory and then from January 2013 to April 2013, as a managing director. Prior to joining Evercore, Mr. Goater served as the Vice President, Pharmaceutical Equity Research at Cowen and Company, and as a business development consultant and acting Chief Executive Officer of LAGeT, Inc. Mr. Goater received a B.A., an M.S. and an M.B.A. from the University of Rochester. We believe that Mr. Goater’s experience as a finance and business development executive in the pharmaceutical industry and his experience in investment banking give him the qualifications and skills to serve on our board of directors.


Bala S. Manian, Ph.D.

Bala S. Manian, Ph.D. has served as a member of our board of directors since December 2004. Dr. Manian has also served as chairman of the board of directors of ReaMetrix Inc., a privately held biotechnology company, since founding the company in 2004. He also currently serves as a director of Biocon Ltd., a publicly traded Indian biopharmaceutical company. Dr. Manian is a co-founder and director of Quantum Dot Corporation, a privately held bioscience company, and a co-founder of SurroMed, Inc., a privately held biotechnology company. He was also the founder and chairman of the board of directors of Lumisys Incorporated, a publicly traded medical imaging company, the founder and chairman of the board of directors of Molecular Dynamics Incorporated, a publicly traded life science instrumentation company, and the founder and chairman of the board of directors of Biometric Imaging Inc., a privately held biotechnology company. Dr. Manian received a B.S. in Physics from the University of Madras, an M.S. in Applied Optics from the University of Rochester and a Ph.D. in Mechanical Engineering from Purdue University. We believe that Dr. Manian’s experience as a founder of numerous biotechnology companies and his service as a director of other publicly traded and privately held life science companies give him the qualifications and skills to serve on our board of directors.


Gerald E. Van Strydonck

Gerald E. Van Strydonck has served as a member of our board of directors since March 2003. Since August 2008, Mr. Van Strydonck has served as the Chief Financial Officer of Colgate Rochester Crozer Divinity School. Since October 2006, he has also served as a contract Chief Financial Officer of Logical Images, Inc., a privately held medical technology company. Mr. Van Strydonck was previously the Senior Vice President and Chief Financial Officer of Sigma Marketing LLC, the Senior Vice President and Chief Financial Officer of Essex Partners Inc., and a managing partner at PricewaterhouseCoopers LLP. Mr. Van Strydonck has also served on the boards of privately held companies. Mr. Van Strydonck received a B.B.A. from St. John Fisher College and an M.B.A. from the State University of New York at Buffalo. We believe that Mr. Van Strydonck’s experience in public accounting and as a Chief Financial Officer of various companies and his service as a director give him the qualifications, skills and financial expertise to serve on our board of directors.


Barbara Yanni

Barbara Yanni has served as a member of our board of directors since February 2015. Ms. Yanni was Vice President and Chief Licensing Officer at Merck & Co., Inc., a publicly traded pharmaceutical company, from November 2001 until her retirement in March 2014. Prior to this, Ms. Yanni served in various roles at Merck including in corporate development, financial evaluation and tax. She currently serves on the boards of Trevena, Inc., a publicly traded biopharmaceutical company, and also serves on the board of a privately held biopharmaceutical company. Ms. Yanni received an A.B. from Wellesley College, a J.D. from Stanford Law School and an LL.M. from New York University. We believe that Ms. Yanni’s experience in biotechnology and pharmaceutical business evaluation and transaction execution, her financial and general business knowledge, and her service as a director of other publicly traded and privately held life science companies give her the qualifications, skills and financial expertise to serve on our board of directors.